Search tips
Search criteria 


Logo of ijpsychHomeCurrent issueInstructionsSubmit article
Indian J Psychiatry. 2004 Oct-Dec; 46(4): 333–341.
PMCID: PMC2950952

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression


The present randomized, double blind, parallel group, controlled, multi-centric trial was designed to evaluate the efficacy and tolerability of escitalopram in comparison with citalopram and sertraline in the treatment of major depressive disorder. Outpatients (N=214) with an ongoing/newly diagnosed ICD-10 major depressive episode and a Hamilton Rating Scale for Depression (HAM-D) score of > 18 were randomly assigned to citalopram, 20–40 mg/day (74 patients), escitalopram, 10–20 mg/day (69 patients) and sertraline, 50-150 mg/day (71 patients), for a 4-week double-blind treatment period, with dosage adjustment (after 2 weeks of treatment) according to the response to treatment. Clinical response was evaluated by the 17 items HAM-D and the Clinical Global Impression (CGI) scales, which were recorded at baseline and at weekly intervals. Tolerability was evaluated by observed/spontaneously reported adverse changes in laboratory parameters (baseline and after 4 weeks). Response rate was defined as a decrease in HAM-D score by 50% from baseline and remission rate was defined as a HAM-D score of < 8. Response rate at the end of two week were 58% for escitalopram (10mg/day), 49% for citalopram (20mg/day) and 52% for sertraline (50-100mg/day). Response rate at the end of four week were 90% for escitalopram (10-20mg/day), 86% for citalopram (20-40mg/day) and 97% for sertraline (100-150mg/day). The Remission rates at the end of four weeks were 74% for escitalopram, 65% for citalopram and 77% for sertraline. Adverse experiences were reported by 45% of patients in escitalopram group, 58% patients in citalopram and 56% patients in the sertraline group. Additionally, there were lesser dropouts and lesser requirement for dose escalation in escitalopram than in citalopram and sertraline group. In conclusion Escitalopram, the Senantiomer of the citalopram is a safe and effective antidepressant in the Indian population. It has potentially superior efficacy than citalopram and a comparable efficacy to sertraline with fewer side effects than both citalopram and sertraline.

Keywords: Escitalopram, Sertraline, Citalopram, SSRI′s

Full Text

The Full Text of this article is available as a PDF (985K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Azorin J-M, Llorca P-M, Despiegel N, Verpillat P. Traitement des épisodes dépressifs sévères: escitalopram est plus efficace que citalopram. Encephale. 2004 Mar-Apr;30(2):158–166. [PubMed]
  • Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs. 1996;52 (Suppl 5):1–12. [PubMed]
  • Hyttel J, Bøgesø KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157–160. [PubMed]
  • Keller MB. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. J Clin Psychiatry. 2000 Dec;61(12):896–908. [PubMed]
  • Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol. 2001 May;88(5):282–286. [PubMed]
  • Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 Sep 1;50(5):345–350. [PubMed]
  • Sánchez Connie, Bøgesø Klaus P, Ebert Bjarke, Reines Elin Heldbo, Braestrup Claus. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004 Jul;174(2):163–176. [PubMed]
  • Tucker GT. Chiral switches. Lancet. 2000 Mar 25;355(9209):1085–1087. [PubMed]
  • Willetts J, Lippa A, Beer B. Clinical development of citalopram. J Clin Psychopharmacol. 1999 Oct;19(5 Suppl 1):36S–46S. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Medknow Publications